Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00351-1
Affiliations:
18
Authors:
17
Go to article
Institutions Authors Share
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada
2.000000
 0.12
McGill University Health Centre (MUHC), Canada
2.000000
 0.12
Hospital of the University of Montreal (CHUM), Canada
2.000000
 0.12
Credit Valley Hospital, Canada
1.000000
 0.06
BC Cancer Agency (BCCA), PHSA, Canada
1.000000
 0.06
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec (CIUSSS MCQ), Canada
1.000000
 0.06
Dalhousie University, Canada
1.000000
 0.06
Charles LeMoyne Hospital, Canada
1.000000
 0.06
CHU de Québec, UL, Canada
1.000000
 0.06
London Health Sciences Centre (LHSC), Canada
1.000000
 0.06
CancerCare Manitoba (CCMB), Canada
1.000000
 0.06
Princess Margaret Cancer Centre, U of T, Canada
1.000000
 0.06
McMaster University, Canada
0.500000
 0.03
Juravinski Cancer Centre, HHS, Canada
0.500000
 0.03
Hôpital de Gatineau, Canada
0.500000
 0.03
McGill University, Canada
0.500000
 0.03
Interested in Biomedical Engineering?